Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). [electronic resource]
Producer: 20160307Description: 277-86 p. digitalISSN:- 1776-260X
- Administration, Intravenous
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antimetabolites, Antineoplastic -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bevacizumab -- administration & dosage
- Carcinoma, Renal Cell -- drug therapy
- Cell Separation -- methods
- Chemotherapy, Adjuvant
- Deoxycytidine -- administration & dosage
- Disease Progression
- Disease-Free Survival
- Female
- Flow Cytometry
- Fluorouracil -- administration & dosage
- Humans
- Immunotherapy -- adverse effects
- Interferon alpha-2
- Interferon-alpha -- administration & dosage
- Interleukin-2 -- administration & dosage
- Italy
- Kaplan-Meier Estimate
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Nephrectomy
- Recombinant Proteins -- administration & dosage
- T-Lymphocytes, Regulatory -- drug effects
- Time Factors
- Treatment Outcome
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.